How does complement damage the neuromuscular junction in gMG?

Apr 6, 2025 ... Eculizumab, a humanized anti-C5 monoclonal antibody, has been the standard of care for treating aHUS, and has been shown to be effective in ... Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data. Feb 7, 2024 ... Eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive refractory generalized myasthenia gravis (gMG). Mar 30, 2022 ... What Are Warnings and Precautions for Eculizumab? · Discontinue if being treated for serious meningococcal infection · Supplement dose with ... A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... ECULIZUMAB (ek yoo LYE zyoo mab) treats certain blood conditions that can cause low levels of red blood cells (anemia) and blood clots. Mar 15, 2025 ... The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to ... Aug 24, 2023 ... Pioneering treatment highly effective for rare kidney disease ... A pioneering drug for a rare kidney disease prevents organ failure and ...